NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Kiniksa reported second quarter financial results and portfolio execution.
Kiniksa's Q2 2023 saw ARCALYST net product revenue reach $54.5 million. The company has increased its ARCALYST 2023 net product revenue guidance to $220 - $230 million. Cash reserves are now expected to fund operations into at least 2027.
- ARCALYST Q2 2023 net product revenue was $54.5 million.
- ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint.
- KPL-404 Phase 2 rheumatoid arthritis data is expected in 1H 2024.
- Cash reserves are now expected to fund operations into at least 2027.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$71.5M
Revenue by segment
Kiniksa · $54.5M total across 1 segment · Q2 2023
- ARCALYST$54.5M+101.9%100.0%
Forward guidance
Kiniksa increased its ARCALYST 2023 net product revenue guidance and expects cash reserves to fund operations into at least 2027.
Tailwinds
- ARCALYST full-year 2023 net product revenue will be between $220 million and $230 million
- Report data from Phase 2 clinical trial of KPL-404 in rheumatoid arthritis in the first half of 2024
- Cash reserves funding current operating plan into at least 2027
- Using KPL-404 to disrupt the CD40-CD154 interaction is an attractive approach to address multiple autoimmune disease pathologies
- Product candidates offer the potential for differentiation
Headwinds
- Delays or difficulty in enrollment of patients in, and activation or continuation of sites for, clinical trials
- Delays or difficulty in completing clinical trials as originally designed
- Potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials
- Inability to replicate results from earlier clinical trials or studies
- Impact of additional data from other companies, including the potential for data to produce negative, inconclusive or commercially uncompetitive results
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro